Physician profile
Lino Ramirez
NPI 1730903790
$412.40
in general payments reported to CMS, 2019-2025
14 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66.43 | 2025 | Airsupra, Farxiga |
| Eisai INC. | $46.77 | 2025 | |
| Boston Scientific Corporation | $43.34 | 2025 | Watchman Flx |
| Pfizer INC. | $34.32 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.88 | 2025 | |
| Amgen INC. | $28.86 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $27.15 | 2025 | Capvaxive |
| Novo Nordisk INC | $21.04 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.04 | 2025 | Xifaxan |
| Exact Sciences Corporation | $20.67 | 2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $19.20 | 2025 | |
| Abbvie INC. | $18.05 | 2025 | |
| Lilly USA, LLC | $16.58 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $16.07 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lino Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.